NCT06152367View on ClinicalTrials.gov

Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 30, 2001

Primary Completion Date

October 9, 2004

Study Completion Date

October 9, 2004

Conditions
Stage III Malignant Melanoma of Skin AJCC V6Stage IV Malignant Melanoma of Skin
Interventions
BIOLOGICAL

TAPCells vaccine

Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.

Trial Locations (1)

8380000

Faculty of Medicine, University of Chile, Santiago

All Listed Sponsors
lead

University of Chile

OTHER

NCT06152367 - Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | Biotech Hunter | Biotech Hunter